Sevenless Therapeutics ApS: Financial statements 2023
CVR: 43311999
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Sevenless Therapeutics ApS (CVR 43311999) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -691,735 and a net result of DKK -103,456. Equity in the 2023 report amounted to DKK 111,937. The solvency ratio was 0.9%.
- Gross Profit
- DKK -691,735
- Profit/Loss
- DKK -103,456
- Equity
- DKK 111,937
- Total Assets
- DKK 12,016,546
- Employees
- 0
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Sevenless Therapeutics ApS has published its interim report for the period June 6, 2022 to December 31, 2022.
About Sevenless Therapeutics ApS
Sevenless Therapeutics ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2022. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Alasdair Naylor, Alexander Robert Leech and Neil Benson. The company is owned by Sevenless Therapeutics Limited. According to the 2025 annual report, the company had an average of 3 employees. In 2025, the company reported a gross profit of DKK -197,098 and a net result of DKK -159,621 compared with DKK -597,179 the year before. Equity in the 2025 report amounted to DKK -644,863.